Hamstringing the FDA: Implications of Overturning the Chevron Doctrine

Session Description: 

During their current term, the U.S. Supreme Court could overturn the so-called “Chevron doctrine” coined by the case Chevron, U.S.A., Inc. v. the Natural Resources Defense Council, Inc. The Chevron doctrine grants federal agencies the freedom to interpret ambiguous laws and statutes passed by Congress. Though the case to be argued, Loper Bright Enterprises., Inc. v. Raimondo (“Loper”) and Relentless v. Department of Commerce (“Relentless”), deals specifically with a regulatory interpretation surrounding overfishing, the ultimate decision will have far-reaching repercussions. If the court overturns or limits the Chevron Doctrine, it would have implications for all federal agencies, policymakers, and physicians.

Join the FDA Task Force to explore the the impact of the potential elimination of the Chevron doctrine, including the FDA’s ability to implement laws related to therapeutic drug approval processes and patient safety.  RSVP now!